The invention relates to a compound of general formula (I) wherein Ar1/Ar2 are independently from each other phenyl or pyridinyl, which are optionally substituted by one or two substituents, selected from the group consisting of halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, lower alkyl substituted by alkoxy, lower alkyl substituted by cyano, lower di-alkyl amino, pyridinyl or cyano R1 is hydrogen, lower alkyl, -(CH2)2O-lower alkyl, or cycloalkyl: R2 is -S(O)2-lower alkyl or -C(O) -lower alkyl or R1 and R2 form together with the N-atom to which they are attached a pyrrolidin-2- one or a piperidin-2-one group R3 is hydrogen, halogen or lower alkyl R4 is hydrogen or lower alkyl R5/R5 are independently from each other hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy or cycloalkyl or R5 and R5 form together with the carbon-atom to which they are attached a cycloalkyl group or to a pharmaceutically active salt thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinsons disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).La présente invention concerne un composé de formule générale (I) dans laquelle Ar1/Ar2 représentent indépendamment lun de lautre un groupe phényle ou pyridinyle, qui sont éventuellement substitués par un ou deux substituants, choisis dans le groupe constitué dun atome dhalogène, des groupes alkyle inférieur, alcoxy inférieur, alkyle inférieur substitué par un atome dhalogène, alcoxy inférieur substitué par un atome dhalogène, alkyle inférieur substitué par un groupe alcoxy, alkyle inférieur substitué par un groupe cyano, dialkylamino inférieur, pyridinyle ou cyano R1 représente un atome dhydrogène, un groupe alkyle inférieur, -(CH2)2O-alkyle inférieur ou cycloalkyle R2 représente un groupe -S(O)2-alkyle inférieur ou -
